# Mecasermin (Increlex)

> Recombinant human IGF-1 for severe primary IGF-1 deficiency.

Source: https://peptides.cafe/peptide/mecasermin
Category: IGF-1 · Endocrine
Tag: FDA-Approved · Endocrine

## Mechanism
Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.

## Research areas
- Severe primary IGF-1 deficiency
- Growth failure with GH gene deletion and neutralizing GH antibodies

## Common research protocols
- Twice-daily SC: 0.04–0.12 mg/kg SC twice daily, given with a meal/snack.

## Study summaries
- "Mecasermin in severe primary IGFD" — JCEM (2007): Improved height velocity over multi-year follow-up.

## Considerations
- FDA-approved.
- Hypoglycemia — must be taken with food.
- Tonsillar hypertrophy, intracranial hypertension reported.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.